| Katie Clark Wadlington, MD | |
|
5921 Riley Park Dr, Fort Smith, AR 72916-6103 | |
| (479) 649-3376 | |
| Not Available |
| Full Name | Katie Clark Wadlington |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 6 Years |
| Location | 5921 Riley Park Dr, Fort Smith, Arkansas |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417445180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | E-15363 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| David E Schoenfeld Md Pc | 1456397660 | 7 |
News Archive
Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.
With their excellent sensitivity and specificity, the use of these extremely efficient tests on a world-wide scale would allow us to adapt antibiotic treatments to the individual's needs and to be more successful in controlling antibiotic resistance, particularly in hospitals.
The World Health Organization (WHO) has urged governments to require that all tobacco packages include pictorial warnings to show the sickness and suffering caused by tobacco use.
Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
› Verified 2 days ago
| Entity Name | David E Schoenfeld Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780658203 PECOS PAC ID: 1456397660 Enrollment ID: O20050628000964 |
News Archive
Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.
With their excellent sensitivity and specificity, the use of these extremely efficient tests on a world-wide scale would allow us to adapt antibiotic treatments to the individual's needs and to be more successful in controlling antibiotic resistance, particularly in hospitals.
The World Health Organization (WHO) has urged governments to require that all tobacco packages include pictorial warnings to show the sickness and suffering caused by tobacco use.
Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Katie Clark Wadlington, MD 7108 Forest Canyon Dr, Fort Smith, AR 72916-4078 Ph: (318) 243-7458 | Katie Clark Wadlington, MD 5921 Riley Park Dr, Fort Smith, AR 72916-6103 Ph: (479) 649-3376 |
News Archive
Researchers have demonstrated the safety of a potential vaccine against mesothelioma, a rare cancer associated primarily with asbestos exposure. The vaccine, which infuses uses a patient's own dendritic cells (DC) with antigen from the patient's tumor, was able to induce a T-cell response against mesothelioma tumors.
With their excellent sensitivity and specificity, the use of these extremely efficient tests on a world-wide scale would allow us to adapt antibiotic treatments to the individual's needs and to be more successful in controlling antibiotic resistance, particularly in hospitals.
The World Health Organization (WHO) has urged governments to require that all tobacco packages include pictorial warnings to show the sickness and suffering caused by tobacco use.
Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.
› Verified 2 days ago
Cyril E Severns, MD Dermatology Medicare: Medicare Enrolled Practice Location: 7900 Dallas St, Fort Smith, AR 72903 Phone: 479-242-6647 Fax: 479-250-0505 | |
Chelsea Jones Meltzer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5921 Riley Park Dr, Fort Smith, AR 72916 Phone: 479-649-3376 | |
Dr. George Luke Lewis, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7900 Dallas Street, Fort Smith, AR 72903 Phone: 479-242-6647 Fax: 479-250-0505 | |
Dr. Sandra Marchese Johnson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5921 Riley Park Dr, Fort Smith, AR 72916 Phone: 479-420-1221 Fax: 479-646-0133 | |
Dr. Brad Russell Johnson, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9207 Highway 71 S, Suite 9, Fort Smith, AR 72916 Phone: 479-649-3376 Fax: 479-646-0133 | |
Dr. Jack L Magness Jr., MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 6801 Rogers Ave, Fort Smith, AR 72903 Phone: 479-274-2000 Fax: 479-274-2194 |